Next-Gen Immunoassay Kit for Influenza a B and Adenovirus

Name: Next-Gen Immunoassay Kit for Influenza a B and Adenovirus
Brand: Beijing Bohui Innovation Biotechnology Group Co., Ltd
SKU: 2152755292

Beijing, ChinaBeijing Bohui Innovation Biotechnology Group Co., Ltd

US$800.00-1,000.00

1 Piece

Product profile

Customization

Available

Classification

Biological Diagnostics

Type

Antigen Testing Device

Model NO.

BH400-II

Certification

CE, ISO13485

Group

Full Range

Transport Package

Piece

Origin

Beijing

HS Code

9027509090

Company profile

Importers and ExportersHigh Repeat Buyers ChoiceExperienced TeamSelf-branded

Beijing Bohui Innovation Biotechnology Group Co., Ltd

Beijing, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples, Customization from Designs, etc. CertifiedExport Year: 1 year CertifiedNearest Port: Tianjin PortAverage Response Time: ≤7.83h

AI-Powered supplier vetting

SummaryBohui Group is a Beijing-based high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. It reports CE and other product certifications, ISO9001:2015, ISO45001:2018, and ISO14001 management certifications. The supplier maintains documented procedures and records for corrective actions, complaint handling, supplier approval, and service assessment. It reports recent new-product activity and broad customization options, but does not provide 3D software design services. Service reach is limited: no overseas agents, branches, warehouses, or showrooms are reported, although the supplier has participated in WHX Labs Dubai 2026 and identifies Tianjin Port as its nearest port. Inventory capability and stated lead times within 15 workdays are reported. Manufacturing capacity is not supported by a valid contract with its affiliated subcontractor. Financial credibility cannot be determined from the provided financial information, and no customer cases are explicitly identified.

Supplier typeThe supplier is described as a combined company and a high-tech biomedical enterprise integrating R&D, production, sales, and after-sales service. Its stated business scope covers technical development and sales of medical devices, medical analysis instruments, and related equipment.

CertificationsThe supplier reports CE and other product compliance certifications, plus ISO9001:2015, ISO45001:2018, ISO14001, and other management-system certifications. It also reports an environmental impact assessment report, providing explicit evidence of certification and environmental documentation.

After-Sales capabilityDocumented procedures and followed records exist for corrective and preventive actions, customer complaints, supplier approval, and service-capability assessment. However, the supplier reports no overseas agents or branches, overseas warehouse, or overseas showroom; it does report inventory capability, participation in WHX Labs Dubai 2026, and lead times within 15 workdays.

R&D capabilityThe company operates a 40,000 square-meter R&D center and reports R&D capability with new products introduced during the past year. Its business scope also includes technical development of medical devices and analytical instruments.

Production capacityThe supplier reports in-stock capability and order fulfillment within 15 workdays during both peak and off-season periods. However, it explicitly lacks a valid manufacturing-capacity contract with its factory and affiliated subcontractor, so production capacity is not fully secured by the provided evidence.

Customization capabilityThe supplier explicitly offers customization from samples, customization from designs, full customization, minor customization, and flexible customization. It does not provide 3D software design services, but the stated customization coverage is broad.